Objective: A recent expert study (RAND Appropriateness Method (RAM)) including a panel of 12 European urologists reported that the PCA3 score may be instrumental in taking appropriate prostate biopsy (PBx) decisions, mainly for repeat PBx.
This study determined the cost/benefit balance of introducing PCA3 in the decision-making for PBx in France.
Methods: Two RAM models, without and with PCA3, were retrospectively applied to a sample of 808 French men who had PBx in 2010 (78% first, 22% repeat). Outcome measures included the proportion of PBx that could have been avoided (i.e., judged inappropriate) in the French sample according to both RAM models, and the estimated impact of application of these models on the annual number of PBx and associated costs for France (based on most recent published data).
Results: Complete profiles were available for 698 men. In the model without PCA3, 2% of PBx were deemed inappropriate. Knowledge of PCA3 would have avoided another 7% of PBx. Repeat PBx would have been avoided in 5% of cases without PCA3 and in 37% with PCA3. For France, application of the RAM model including PCA3 would result in 18,345 fewer repeat PBx. It would be budget-neutral in the unlikely hypothesis of no complications or no costs incurred by complications and would save €1.7 million for a mean cost for complications of €100/procedure or €5 million for a mean cost for complications of €280/procedure, calculated based on US and Canadian data. Limitations: Limitations of the study are the theoretical nature of the analysis and the fact that PCA3 distributions had to be derived from other sources.
Conclusions: Adoption of RAM expert recommendations including PCA3 for repeat PBx decisions in clinical practice in France would reduce the number of repeat PBx and control costs.
Written by:
Malavaud B, Cussenot O, Mottet N, Rozet F, Ruffion A, Smets L, Stoevelaar H. Are you the author?
CHU de Toulouse, Hôpital de Rangueil, Toulouse, France.
Reference: J Med Econ. 2012 Dec 19. Epub ahead of print.
doi: 10.3111/13696998.2012.757552
PubMed Abstract
PMID: 23231342
Go "Beyond the Abstract" - Read an article written by the authors for UroToday.com
UroToday.com Prostate Cancer Section
